In rare disease and genetically stratified trials, recruitment often depends on a single critical step: confirming that a patient carries the relevant genetic variant.
Unlike traditional studies, eligibility is not determined solely by clinical phenotype or diagnosis. Patients must first understand, consent to, and complete genetic testing. Only then can they be screened for participation.
This requirement introduces a distinct and often underestimated barrier. Patients are not only being asked to join a clinical trial. They are being asked to engage with genetic testing, interpret conversations with genetic counselors, and consider implications for themselves and their families.
When patients do not fully understand why genetic testing is required, how it works, or what the results may mean, they are significantly less likely to proceed. Some drop out before testing, while others decline consent altogether. In many cases, these patients never enter the recruitment funnel in a measurable way.
For sponsors and clinical operations teams running variant-driven trials, genetic literacy is therefore not a secondary consideration. It is a gating factor that directly determines how many patients can even be evaluated for eligibility.
In trials where eligibility depends on a specific mutation or variant, recruitment is inherently a two-step process.
First, patients must be identified and agree to genetic testing. Second, only a subset of those patients will meet the genetic criteria required for enrollment.
This creates a funnel with significant early attrition. If patients do not understand the purpose or implications of genetic testing, they may never complete the first step. As a result, the pool of genetically confirmed patients remains artificially constrained.
This issue is particularly pronounced in rare diseases, where patients may already face long diagnostic journeys and varying levels of exposure to genetic concepts. Even within engaged patient communities, understanding of testing modalities, result interpretation, and data usage is inconsistent.
From an operational perspective, this often appears as slow enrollment or underperforming sites. This may be interpreted as limited prevalence or overly restrictive criteria. In reality, the constraint exists earlier in the pathway at the point of genetic engagement.
The consequences can be significant:
In rare disease trials, where patient populations are inherently limited, this inefficiency is amplified. Small losses at the testing stage translate into large impacts on final cohort size.
In practice, several patterns consistently limit recruitment in precision trials.
One of the most common is assuming that patients understand why genetic testing is necessary. While this may be true for a subset of highly informed patients, many individuals do not immediately grasp the link between a genetic variant and eligibility for a therapy. Without this context, testing can feel optional, invasive, or irrelevant.
Another issue is how genetic testing is presented. Patient-facing materials often emphasize procedural details but fail to clearly explain the purpose of testing in relation to the trial. This disconnect reduces motivation to proceed.
Timing also plays a role. Genetic testing is frequently introduced late in the recruitment process, after initial engagement has already occurred. At that point, introducing a new and complex requirement can create friction and lead to drop-off.
There is also a tendency to underestimate concerns around data use and privacy. Patients may hesitate to undergo testing if they are unsure how their genetic information will be stored, shared, or used beyond the study.
Finally, recruitment workflows often treat genetic testing as a logistical step rather than a behavioral one. The focus is placed on kit distribution and sample return rates, rather than on whether patients feel confident and informed enough to complete the process.
Improving genetic literacy in genetic trials requires focusing specifically on the decision to undergo testing.
Patients need clear answers to three questions early in the journey:
Clarity across these dimensions reduces uncertainty and increases the likelihood that patients will complete testing.
Equally important is when and how this information is delivered. Introducing genetic concepts early, ideally at the first point of engagement, allows patients to process the information before being asked to take action. Reinforcing these concepts at key moments helps maintain confidence and momentum.
For clinical operations teams, the most effective approach is to embed genetic education directly into recruitment pathways, in language that is easy to understand, rather than treating it as a separate layer.
Pre-screening is a critical opportunity. Digital tools and outreach channels can be used not only to identify potential participants but also to explain the role of genetic testing upfront. This ensures that patients entering the funnel are already aligned with the study requirements.
During the testing phase, clear and accessible guidance can reduce drop-off. This includes instructions, expectations, and reassurance around data handling. Small uncertainties at this stage can have a disproportionate impact on completion rates.
Site staff and patient-facing teams also play an important role. They need to be equipped to explain genetic concepts consistently and confidently. Variability in how testing is communicated can lead to inconsistent patient decisions and outcomes.
From a systems perspective, integrating education with logistics allows sponsors to track where drop-off occurs and why. This creates the ability to optimize not only operational steps but also patient understanding.
When genetic literacy is addressed effectively, the impact is visible across the recruitment funnel.
More patients agree to testing, increasing the size of the genetically screened population. Completion rates improve, reducing delays associated with sample return and processing. As a result, more eligible patients are identified earlier in the study.
This leads to faster enrollment and more predictable timelines. It also reduces the cost associated with repeated outreach and underperforming sites.
Importantly, improving understanding can also broaden access. Patients who might otherwise decline testing due to uncertainty or mistrust are more likely to participate when information is clear and relevant. This supports more representative cohorts, which is particularly important in rare disease research.
In precision trials, If patients do not understand or feel comfortable with genetic testing, they never reach the point of eligibility. This makes genetic literacy a primary determinant of recruitment success rather than a secondary consideration.
Sponsors who recognize this can redesign their approach to recruitment, integrating clear, early, and continuous education around genetic testing. Those who do not will continue to face constrained funnels and prolonged timelines, even in studies with strong scientific rationale.
As more therapies target specific genetic variants, this challenge will only become more pronounced. Addressing genetic literacy now is essential for executing these trials effectively.
To explore how Sano Genetics can support patient education and engagement around genetic testing for precision trials, get in touch.